vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and REGIS CORP (RGS). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $57.1M, roughly 1.5× REGIS CORP). On growth, REGIS CORP posted the faster year-over-year revenue change (22.3% vs 17.7%). REGIS CORP produced more free cash flow last quarter ($891.0K vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 7.8%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
REGIS CORPRGSEarnings & Financial Report
Regis Corporation is an American operator of hair salons. As of August 2021, it has 5,563 franchised and 276 company-owned salons. Its headquarters are in Minneapolis, Minnesota.
IOVA vs RGS — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $57.1M |
| Net Profit | — | $456.0K |
| Gross Margin | 67.4% | — |
| Operating Margin | -84.7% | 10.8% |
| Net Margin | — | 0.8% |
| Revenue YoY | 17.7% | 22.3% |
| Net Profit YoY | — | -94.0% |
| EPS (diluted) | — | $0.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $57.1M | ||
| Q3 25 | $67.5M | $59.0M | ||
| Q2 25 | $60.0M | $60.4M | ||
| Q1 25 | $49.3M | $57.0M | ||
| Q4 24 | $73.7M | $46.7M | ||
| Q3 24 | $58.6M | $46.1M | ||
| Q2 24 | $31.1M | $49.4M | ||
| Q1 24 | $715.0K | $49.2M |
| Q4 25 | — | $456.0K | ||
| Q3 25 | $-91.3M | $1.4M | ||
| Q2 25 | $-111.7M | $116.5M | ||
| Q1 25 | $-116.2M | $250.0K | ||
| Q4 24 | — | $7.6M | ||
| Q3 24 | $-83.5M | $-853.0K | ||
| Q2 24 | $-97.1M | $91.2M | ||
| Q1 24 | $-113.0M | $-2.3M |
| Q4 25 | 67.4% | — | ||
| Q3 25 | 43.0% | — | ||
| Q2 25 | 5.5% | — | ||
| Q1 25 | -0.8% | — | ||
| Q4 24 | 68.7% | — | ||
| Q3 24 | 46.2% | — | ||
| Q2 24 | -0.8% | — | ||
| Q1 24 | — | — |
| Q4 25 | -84.7% | 10.8% | ||
| Q3 25 | -140.7% | 10.0% | ||
| Q2 25 | -189.8% | 12.1% | ||
| Q1 25 | -245.8% | 8.8% | ||
| Q4 24 | -117.5% | 11.8% | ||
| Q3 24 | -152.1% | 4.6% | ||
| Q2 24 | -327.6% | — | ||
| Q1 24 | -16464.6% | 8.3% |
| Q4 25 | — | 0.8% | ||
| Q3 25 | -135.3% | 2.3% | ||
| Q2 25 | -186.2% | 192.9% | ||
| Q1 25 | -235.5% | 0.4% | ||
| Q4 24 | — | 16.4% | ||
| Q3 24 | -142.7% | -1.9% | ||
| Q2 24 | -312.2% | 184.7% | ||
| Q1 24 | -15800.8% | -4.7% |
| Q4 25 | — | $0.16 | ||
| Q3 25 | — | $0.49 | ||
| Q2 25 | $-0.33 | $43.67 | ||
| Q1 25 | $-0.36 | $0.08 | ||
| Q4 24 | $-0.24 | $2.71 | ||
| Q3 24 | $-0.28 | $-0.36 | ||
| Q2 24 | $-0.34 | $38.40 | ||
| Q1 24 | $-0.42 | $-1.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $18.4M |
| Total DebtLower is stronger | — | $113.3M |
| Stockholders' EquityBook value | $698.6M | $188.7M |
| Total Assets | $913.2M | $588.3M |
| Debt / EquityLower = less leverage | — | 0.60× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | $18.4M | ||
| Q3 25 | $300.8M | $16.6M | ||
| Q2 25 | $301.2M | $17.0M | ||
| Q1 25 | $359.7M | $13.3M | ||
| Q4 24 | $323.8M | $10.2M | ||
| Q3 24 | $397.5M | $6.3M | ||
| Q2 24 | $412.5M | $10.1M | ||
| Q1 24 | $356.2M | $5.9M |
| Q4 25 | — | $113.3M | ||
| Q3 25 | — | $111.3M | ||
| Q2 25 | — | $110.8M | ||
| Q1 25 | — | $112.0M | ||
| Q4 24 | — | $111.5M | ||
| Q3 24 | — | $95.2M | ||
| Q2 24 | — | $99.5M | ||
| Q1 24 | — | $179.7M |
| Q4 25 | $698.6M | $188.7M | ||
| Q3 25 | $702.3M | $187.6M | ||
| Q2 25 | $698.5M | $185.6M | ||
| Q1 25 | $767.9M | $68.6M | ||
| Q4 24 | $710.4M | $66.7M | ||
| Q3 24 | $773.5M | $56.4M | ||
| Q2 24 | $768.5M | $56.8M | ||
| Q1 24 | $680.0M | $-35.8M |
| Q4 25 | $913.2M | $588.3M | ||
| Q3 25 | $904.9M | $592.1M | ||
| Q2 25 | $907.4M | $599.0M | ||
| Q1 25 | $966.7M | $511.2M | ||
| Q4 24 | $910.4M | $530.1M | ||
| Q3 24 | $991.1M | $508.9M | ||
| Q2 24 | $964.3M | $530.5M | ||
| Q1 24 | $869.8M | $543.7M |
| Q4 25 | — | 0.60× | ||
| Q3 25 | — | 0.59× | ||
| Q2 25 | — | 0.60× | ||
| Q1 25 | — | 1.63× | ||
| Q4 24 | — | 1.67× | ||
| Q3 24 | — | 1.69× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $1.7M |
| Free Cash FlowOCF − Capex | $-61.9M | $891.0K |
| FCF MarginFCF / Revenue | -71.3% | 1.6% |
| Capex IntensityCapex / Revenue | 10.7% | 1.4% |
| Cash ConversionOCF / Net Profit | — | 3.65× |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | $14.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $1.7M | ||
| Q3 25 | $-78.7M | $2.3M | ||
| Q2 25 | $-67.4M | $6.8M | ||
| Q1 25 | $-103.7M | $6.2M | ||
| Q4 24 | $-73.3M | $2.1M | ||
| Q3 24 | $-59.0M | $-1.3M | ||
| Q2 24 | $-98.4M | $5.1M | ||
| Q1 24 | $-122.3M | $-277.0K |
| Q4 25 | $-61.9M | $891.0K | ||
| Q3 25 | $-89.5M | $1.9M | ||
| Q2 25 | $-74.9M | $6.2M | ||
| Q1 25 | $-109.9M | $5.9M | ||
| Q4 24 | $-77.5M | $1.7M | ||
| Q3 24 | $-61.3M | $-1.4M | ||
| Q2 24 | $-98.9M | $5.1M | ||
| Q1 24 | $-126.5M | $-326.0K |
| Q4 25 | -71.3% | 1.6% | ||
| Q3 25 | -132.7% | 3.2% | ||
| Q2 25 | -124.9% | 10.3% | ||
| Q1 25 | -222.8% | 10.3% | ||
| Q4 24 | -105.1% | 3.6% | ||
| Q3 24 | -104.6% | -3.0% | ||
| Q2 24 | -317.9% | 10.3% | ||
| Q1 24 | -17685.3% | -0.7% |
| Q4 25 | 10.7% | 1.4% | ||
| Q3 25 | 16.1% | 0.7% | ||
| Q2 25 | 12.4% | 0.9% | ||
| Q1 25 | 12.6% | 0.6% | ||
| Q4 24 | 5.7% | 0.9% | ||
| Q3 24 | 3.9% | 0.0% | ||
| Q2 24 | 1.4% | 0.0% | ||
| Q1 24 | 583.4% | 0.1% |
| Q4 25 | — | 3.65× | ||
| Q3 25 | — | 1.68× | ||
| Q2 25 | — | 0.06× | ||
| Q1 25 | — | 24.80× | ||
| Q4 24 | — | 0.28× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.06× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
RGS
| Franchise Segment | $37.9M | 66% |
| Royalty | $13.6M | 24% |
| Other | $2.8M | 5% |
| Fees | $1.8M | 3% |
| Franchise Fees | $1.0M | 2% |
